Breaking News
4 hours ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Moleculin Biotech adds Hong Kong to its Annamycin IP portfolio ahead of imminent Phase 3 data, extending formulation exclusivity through 2040.
Pharma Now Editorial Team

FDA's final guidance on postapproval pregnancy safety studies sets a methodological framework covering registries, real-world data, and case-based descriptive studies.
Pharma Now Editorial Team

FDA finalizes pulmonary TB drug development guidance under docket FDA-2013-D-1319, setting clinical trial expectations for antibacterial sponsors.
Pharma Now Editorial Team

FDA finalizes CDI drug development guidance under docket FDA-2022-D-1261, covering treatment, recurrence reduction, and prevention indication pathways.
Pharma Now Editorial Team
